IMMP (Immutep Limited) stock: $0.29, $42.3M market cap, $44.0M cash, -$1.7M EV, $42.4M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
eftilagimod alfa
Phase 3 · Active Modality: recombinant protein
Aliases efti, IMP321
Target LAG-3
Partnerships Merck & Co./MSD (3 clinical trial collaboration and supply agreements for efti + pembrolizumab in Phase II and Phase III trials); Merck KGaA + Pfizer (2 agreements for efti + avelumab in Phase I trials); EOC Pharma (licensee for efti development and manufacturing in China)
Status note Most advanced of five LAG-3 programs. Soluble LAG-3 immune activator used with other therapies to amplify immune response. Specific cancer indications not stated in the filing excerpts.
IMP701
Stage not disclosed · Active
Aliases LAG525, ieramilimab
Target LAG-3
Partnerships Novartis (fully licensed to CoStim Pharmaceuticals, subsequently acquired by Novartis)
Status note Licensed out; stage and indications not stated in filing excerpts.
IMP731
Stage not disclosed · Active
Aliases GSK'781
Target LAG-3
Partnerships GSK
Status note Partnered with GSK; stage and indications not stated in filing excerpts.
anti-LAG-3 small molecule program
Discovery · Active Modality: small molecule
Target LAG-3
Status note Described as a very early stage anti-LAG-3 small molecule program.
IMP761
Stage not disclosed · Active Modality: antibody
Target LAG-3
Indications- autoimmune disease (Stage not disclosed)
Status note Clinical-stage agonist antibody of LAG-3 for application in autoimmune disease; exact phase not stated in filing excerpts.
Per-asset detail extracted from the 20-F filed 2025-10-24. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.